Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476588 · ClinicalTrials.gov registry record · NA
Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform
A NA study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
NCT05476588: Completed NA study, sponsored by Baylor Research Institute.
NCT05476588 is a NA study that has completed, run by Baylor Research Institute. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05476588, a NA study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The goal of this study is to validate the TAPS-ESP as a screen and assessment that can be used in primary care for the screening and treatment of substance use.
Primary Outcome
TAPS-ESP is a two-stage screening and assessment tool that first screens for 4 broad substance abuse categories (tobacco, alcohol, prescription drug misuse, and illicit substances), then branches to the assessment for specific risks related to an array of substances. TAPS-ESP scores will be validated against the modified World Mental Health Composite International Diagnostic Interview (CIDI) including alcohol, tobacco, and 9 substance categories. The CIDI items mapped to the diagnostic criteria
Interventions
- OTHER Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2024-03-14 |
| Phase | NA |
What the finished NCT05476588 record still lists
NCT05476588 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 1 intervention - of which Screening is the first listed.
NCT05476588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05476588 about?
NCT05476588 is a clinical study titled "Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use- Electronic Spanish Platform". The goal of this study is to validate the TAPS-ESP as a screen and assessment that can be used in primary care for the screening and treatment of substance use.
What is the current status of trial NCT05476588?
This trial is currently completed. It is a NA study. The enrollment target is 1,000 participants. The study started on 2022-07-15. Estimated completion is 2024-03-14.
What interventions are being tested in trial NCT05476588?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT05476588?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05476588's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI